Beam Therapeutics Inc. (BEAM) 10-Year Financial Performance & Capital Metrics

BEAM • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

AboutBeam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.Show more

Revenue $64M -83.2%
EBITDA -$394M -167.9%
Net Income -$377M -184.3%
EPS (Diluted) -4.58 -166.3%
Gross Margin -478.67% -578.7%
EBITDA Margin -619.73% -1492.9%
Operating Margin -654.25% -1300.2%
Net Margin -593.13% -1590.4%
ROE -43.94% -184.3%
ROIC -46.83% -147.3%
Debt/Equity 0.22 +25.1%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 91 (top 9%)
✓Strong 5Y sales CAGR of 412.3%

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Negative free cash flow
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y412.3%

3Y7%

TTM-84.07%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-188.77%

EPS CAGR

10Y-

5Y-

3Y-

TTM-151.7%

ROCE

10Y Avg-44.1%

5Y Avg-37.2%

3Y Avg-27.18%

Latest-38.2%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	18K	24K	51.84M	60.92M	377.71M	63.52M
Revenue Growth %	-	-	-	0.33%	2159.17%	0.18%	5.2%	-0.83%
Cost of Goods Sold+	0	33.87M	54.62M	103.18M	232.13M	311.59M	0	367.56M
COGS % of Revenue	-	-	3034.39%	4299.13%	4.48%	5.11%	-	5.79%
Gross Profit+	0	-33.87M	-54.6M	-103.16M	-180.29M	-250.67M	377.71M	-304.04M
Gross Margin %	-	-	-3033.39%	-4298.13%	-3.48%	-4.11%	1%	-4.79%
Gross Profit Growth %	-	-	-0.61%	-0.89%	-0.75%	-0.39%	2.51%	-1.8%
Operating Expenses+	8.6M	11.87M	20.55M	29.6M	212.18M	87.81M	554.19M	111.53M
OpEx % of Revenue	-	-	1141.83%	1233.54%	4.09%	1.44%	1.47%	1.76%
Selling, General & Admin	2.2M	11.87M	20.55M	29.61M	57.22M	87.81M	116.81M	111.53M
SG&A % of Revenue	-	-	1141.83%	1233.54%	1.1%	1.44%	0.31%	1.76%
Research & Development	5.86M	33.87M	54.62M	103.18M	387.09M	311.59M	437.38M	367.56M
R&D % of Revenue	-	-	3034.39%	4299.13%	7.47%	5.11%	1.16%	5.79%
Other Operating Expenses	0	-33.87M	-54.62M	-103.18M	-232.13M	-311.59M	0	-367.56M
Operating Income+	-8.6M	-45.74M	-75.15M	-132.76M	-392.46M	-338.48M	-176.49M	-415.57M
Operating Margin %	-	-	-4175.22%	-5531.67%	-7.57%	-5.56%	-0.47%	-6.54%
Operating Income Growth %	-	-4.32%	-0.64%	-0.77%	-1.96%	0.14%	0.48%	-1.35%
EBITDA+	-8.58M	-45.09M	-71.65M	-128.03M	-385.01M	-324.33M	-146.95M	-393.64M
EBITDA Margin %	-	-	-3980.61%	-5334.38%	-7.43%	-5.32%	-0.39%	-6.2%
EBITDA Growth %	-	-4.25%	-0.59%	-0.79%	-2.01%	0.16%	0.55%	-1.68%
D&A (Non-Cash Add-back)	12K	650K	3.5M	4.73M	7.45M	14.15M	29.53M	21.93M
EBIT	-8.6M	-45.74M	-75.15M	-132.76M	-237.51M	-338.48M	-176.49M	-415.57M
Net Interest Income+	0	0	2.3M	1.57M	0	0	0	49.09M
Interest Income	0	292K	2.49M	1.57M	0	0	0	49.09M
Interest Expense	0	0	187K	0	0	0	0	0
Other Income/Expense	-133.09K	-71M	-3.17M	-61.83M	21.83M	52.8M	45.32M	38.87M
Pretax Income+	-8.73M	-116.74M	-78.33M	-194.59M	-370.64M	-285.68M	-131.16M	-376.7M
Pretax Margin %	-	-	-4351.44%	-8108%	-7.15%	-4.69%	-0.35%	-5.93%
Income Tax+	500K	0	0	0	0	3.41M	1.37M	39K
Effective Tax Rate %	1%	0.99%	1%	1%	1%	1.01%	1.01%	1%
Net Income+	-8.73M	-115.26M	-78.33M	-194.59M	-370.64M	-289.09M	-132.53M	-376.74M
Net Margin %	-	-	-4351.44%	-8108%	-7.15%	-4.75%	-0.35%	-5.93%
Net Income Growth %	-	-12.2%	0.32%	-1.48%	-0.9%	0.22%	0.54%	-1.84%
Net Income (Continuing)	-8.73M	-116.74M	-78.33M	-194.59M	-370.64M	-289.09M	-132.53M	-376.74M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.62	-3.28	-1.53	-5.49	-5.77	-4.13	-1.72	-4.58
EPS Growth %	-	-4.29%	0.53%	-2.59%	-0.05%	0.28%	0.58%	-1.66%
EPS (Basic)	-0.62	-3.28	-1.53	-5.49	-5.77	-4.13	-1.72	-4.58
Diluted Shares Outstanding	12.95M	35.14M	51.34M	46.73M	64.23M	70.02M	77.15M	82.31M
Basic Shares Outstanding	12.95M	35.14M	51.34M	46.73M	64.23M	70.02M	77.15M	82.31M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	2.04M	148.28M	94.54M	308.32M	1.27B	1.09B	1.21B	878.15M
Cash & Short-Term Investments	1.9M	146.44M	91.85M	299.67M	965.65M	1.08B	1.19B	850.74M
Cash Only	1.9M	146.44M	37.22M	162.17M	559.99M	232.77M	435.89M	281.97M
Short-Term Investments	0	0	54.63M	137.5M	405.65M	845.37M	753.98M	568.77M
Accounts Receivable	0	0	0	0	300M	0	0	0
Days Sales Outstanding	-	-	-	-	2.11K	-	-	-
Inventory	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	14.76M	21.17M	27.41M
Total Non-Current Assets+	365K	18.74M	61.55M	143.36M	201.45M	248.82M	248.67M	225.68M
Property, Plant & Equipment	335K	16.94M	43.25M	125.37M	186.98M	234.13M	237.81M	216.28M
Fixed Asset Turnover	-	-	0.00x	0.00x	0.28x	0.26x	1.59x	0.29x
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0
Long-Term Investments	30K	1.49M	0	0	0	0	0	0
Other Non-Current Assets	0	300K	18.31M	17.98M	14.47M	14.69M	10.87M	9.4M
Total Assets+	2.4M	167.01M	156.1M	451.68M	1.47B	1.34B	1.46B	1.1B
Asset Turnover	-	-	0.00x	0.00x	0.04x	0.05x	0.26x	0.06x
Asset Growth %	-	68.53%	-0.07%	1.89%	2.26%	-0.09%	0.09%	-0.24%
Total Current Liabilities+	6.57M	25.59M	29.14M	102.34M	213.44M	223.59M	205.56M	182.07M
Accounts Payable	726K	7.35M	7.85M	6.31M	7.47M	9.03M	1.62M	3.87M
Days Payables Outstanding	-	79.21	52.43	22.34	11.75	10.58	-	3.84
Short-Term Debt	1.01M	0	1.3M	2.12M	2.29M	0	0	0
Deferred Revenue (Current)	-1000K	0	0	24K	1000K	1000K	1000K	1000K
Other Current Liabilities	4.7M	16.54M	12.56M	83.02M	60.83M	49.68M	100.69M	19.74M
Current Ratio	0.31x	5.79x	3.24x	3.01x	5.96x	4.89x	5.89x	4.82x
Quick Ratio	0.31x	5.79x	3.24x	3.01x	5.96x	4.89x	5.89x	4.82x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	20K	7.4M	26.02M	103.78M	434.28M	384.64M	272.82M	188.21M
Long-Term Debt	0	0	4.41M	5.29M	3.01M	0	0	0
Capital Lease Obligations	0	0	21.19M	96.01M	134.81M	168.63M	159.91M	147.96M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	20K	7.4M	418K	2.08M	34.16M	13.84M	3.02M	7.04M
Total Liabilities	6.58M	32.98M	55.15M	206.12M	647.72M	608.24M	478.38M	370.28M
Total Debt+	1.01M	0	31.24M	107.64M	147.64M	179M	172.69M	161.43M
Net Debt	-891K	-146.44M	-5.98M	-54.53M	-412.35M	-53.76M	-263.21M	-120.54M
Debt / Equity	-	-	0.31x	0.44x	0.18x	0.24x	0.18x	0.22x
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-401.89x	-	-	-	-	-
Total Equity+	-4.18M	134.03M	100.94M	245.56M	826.74M	733.47M	981.33M	733.54M
Equity Growth %	-	33.04%	-0.25%	1.43%	2.37%	-0.11%	0.34%	-0.25%
Book Value per Share	-0.32	3.81	1.97	5.25	12.87	10.48	12.72	8.91
Total Shareholders' Equity	-4.18M	134.03M	100.94M	245.56M	826.74M	733.47M	981.33M	733.54M
Common Stock	5K	56K	73K	573K	684K	712K	816K	836K
Retained Earnings	-9.46M	-124.72M	-203.04M	-397.64M	-768.27M	-1.06B	-1.19B	-1.57B
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	-11K	-661K	16K	-9K	-50K	-2.43M	604K	679K
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-2.71M	-20.3M	-72M	-95.74M	-66.27M	22.53M	-149.19M	-347.25M
Operating CF Margin %	-	-	-4000.17%	-3989.21%	-1.28%	0.37%	-0.4%	-5.47%
Operating CF Growth %	-	-6.5%	-2.55%	-0.33%	0.31%	1.34%	-7.62%	-1.33%
Net Income	-8M	-116.74M	-78.33M	-194.59M	-370.64M	-289.09M	-132.53M	-376.74M
Depreciation & Amortization	11K	650K	3.5M	4.74M	7.45M	14.15M	20.01M	21.93M
Stock-Based Compensation	198K	7M	7.03M	15.38M	43.57M	84.32M	98.65M	120.66M
Deferred Taxes	500K	11.75M	0	63.52M	0	0	0	0
Other Non-Cash Items	3.85M	66.96M	6.5M	9.87M	142.09M	-38.48M	-18.87M	-2.87M
Working Capital Changes	740K	10.07M	-10.71M	5.35M	111.25M	251.63M	-116.45M	-110.22M
Change in Receivables	0	0	0	0	-300M	300M	0	0
Change in Inventory	0	0	0	0	0	-300M	0	0
Change in Payables	726K	2.44M	4.09M	60K	818K	2.37M	-7.58M	1.81M
Cash from Investing+	-346K	-13.42M	-66.66M	-100.12M	-294.14M	-461.34M	71.84M	185.01M
Capital Expenditures	-346K	-13.12M	-12.52M	-16.36M	-46.81M	-48.95M	-33.73M	-8.95M
CapEx % of Revenue	-	-	695.44%	681.54%	0.9%	0.8%	0.09%	0.14%
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	0	-300K	0	-83.77M	0	-412.38M	0	0
Cash from Financing+	4.98M	179.73M	41.28M	322.32M	756.14M	111.59M	276.45M	7.74M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	0	10K	-2.34M	1.1M	810K	5.62M	8.53M	0
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-3.05M	-33.42M	-84.52M	-112.1M	-113.08M	-26.42M	-182.93M	-356.19M
FCF Margin %	-	-	-4695.61%	-4670.75%	-2.18%	-0.43%	-0.48%	-5.61%
FCF Growth %	-	-9.95%	-1.53%	-0.33%	-0.01%	0.77%	-5.92%	-0.95%
FCF per Share	-0.24	-0.95	-1.65	-2.40	-1.76	-0.38	-2.37	-4.33
FCF Conversion (FCF/Net Income)	0.31x	0.18x	0.92x	0.49x	0.18x	-0.08x	1.13x	0.92x
Interest Paid	0	0	187K	0	567K	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-177.53%	-66.67%	-112.32%	-69.13%	-37.06%	-15.46%	-43.94%
Return on Invested Capital (ROIC)	-	-	-136.57%	-69.63%	-97.24%	-46.41%	-18.94%	-46.83%
Gross Margin	-	-	-303338.89%	-429812.5%	-347.75%	-411.48%	100%	-478.67%
Net Margin	-	-	-435144.44%	-810800%	-714.91%	-474.54%	-35.09%	-593.13%
Debt / Equity	-	-	0.31x	0.44x	0.18x	0.24x	0.18x	0.22x
Interest Coverage	-	-	-401.89x	-	-	-	-	-
FCF Conversion	0.31x	0.18x	0.92x	0.49x	0.18x	-0.08x	1.13x	0.92x
Revenue Growth	-	-	-	33.33%	215916.67%	17.51%	520.01%	-83.18%

Frequently Asked Questions

Growth & Financials

Beam Therapeutics Inc. (BEAM) reported $55.7M in revenue for fiscal year 2024.

Beam Therapeutics Inc. (BEAM) saw revenue decline by 83.2% over the past year.

Beam Therapeutics Inc. (BEAM) reported a net loss of $414.6M for fiscal year 2024.

Dividend & Returns

Beam Therapeutics Inc. (BEAM) has a return on equity (ROE) of -43.9%. Negative ROE indicates the company is unprofitable.

Beam Therapeutics Inc. (BEAM) had negative free cash flow of $352.4M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Beam Therapeutics Inc. (BEAM) 10-Year Financial Performance & Capital Metrics

BEAM • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

Revenue $64M -83.2%
EBITDA -$394M -167.9%
Net Income -$377M -184.3%
EPS (Diluted) -4.58 -166.3%
Gross Margin -478.67% -578.7%
EBITDA Margin -619.73% -1492.9%
Operating Margin -654.25% -1300.2%
Net Margin -593.13% -1590.4%
ROE -43.94% -184.3%
ROIC -46.83% -147.3%
Debt/Equity 0.22 +25.1%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 91 (top 9%)
✓Strong 5Y sales CAGR of 412.3%

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Negative free cash flow
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y412.3%

3Y7%

TTM-84.07%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-188.77%

EPS CAGR

10Y-

5Y-

3Y-

TTM-151.7%

ROCE

10Y Avg-44.1%

5Y Avg-37.2%

3Y Avg-27.18%

Latest-38.2%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	18K	24K	51.84M	60.92M	377.71M	63.52M
Revenue Growth %	-	-	-	0.33%	2159.17%	0.18%	5.2%	-0.83%
Cost of Goods Sold+	0	33.87M	54.62M	103.18M	232.13M	311.59M	0	367.56M
COGS % of Revenue	-	-	3034.39%	4299.13%	4.48%	5.11%	-	5.79%
Gross Profit+	0	-33.87M	-54.6M	-103.16M	-180.29M	-250.67M	377.71M	-304.04M
Gross Margin %	-	-	-3033.39%	-4298.13%	-3.48%	-4.11%	1%	-4.79%
Gross Profit Growth %	-	-	-0.61%	-0.89%	-0.75%	-0.39%	2.51%	-1.8%
Operating Expenses+	8.6M	11.87M	20.55M	29.6M	212.18M	87.81M	554.19M	111.53M
OpEx % of Revenue	-	-	1141.83%	1233.54%	4.09%	1.44%	1.47%	1.76%
Selling, General & Admin	2.2M	11.87M	20.55M	29.61M	57.22M	87.81M	116.81M	111.53M
SG&A % of Revenue	-	-	1141.83%	1233.54%	1.1%	1.44%	0.31%	1.76%
Research & Development	5.86M	33.87M	54.62M	103.18M	387.09M	311.59M	437.38M	367.56M
R&D % of Revenue	-	-	3034.39%	4299.13%	7.47%	5.11%	1.16%	5.79%
Other Operating Expenses	0	-33.87M	-54.62M	-103.18M	-232.13M	-311.59M	0	-367.56M
Operating Income+	-8.6M	-45.74M	-75.15M	-132.76M	-392.46M	-338.48M	-176.49M	-415.57M
Operating Margin %	-	-	-4175.22%	-5531.67%	-7.57%	-5.56%	-0.47%	-6.54%
Operating Income Growth %	-	-4.32%	-0.64%	-0.77%	-1.96%	0.14%	0.48%	-1.35%
EBITDA+	-8.58M	-45.09M	-71.65M	-128.03M	-385.01M	-324.33M	-146.95M	-393.64M
EBITDA Margin %	-	-	-3980.61%	-5334.38%	-7.43%	-5.32%	-0.39%	-6.2%
EBITDA Growth %	-	-4.25%	-0.59%	-0.79%	-2.01%	0.16%	0.55%	-1.68%
D&A (Non-Cash Add-back)	12K	650K	3.5M	4.73M	7.45M	14.15M	29.53M	21.93M
EBIT	-8.6M	-45.74M	-75.15M	-132.76M	-237.51M	-338.48M	-176.49M	-415.57M
Net Interest Income+	0	0	2.3M	1.57M	0	0	0	49.09M
Interest Income	0	292K	2.49M	1.57M	0	0	0	49.09M
Interest Expense	0	0	187K	0	0	0	0	0
Other Income/Expense	-133.09K	-71M	-3.17M	-61.83M	21.83M	52.8M	45.32M	38.87M
Pretax Income+	-8.73M	-116.74M	-78.33M	-194.59M	-370.64M	-285.68M	-131.16M	-376.7M
Pretax Margin %	-	-	-4351.44%	-8108%	-7.15%	-4.69%	-0.35%	-5.93%
Income Tax+	500K	0	0	0	0	3.41M	1.37M	39K
Effective Tax Rate %	1%	0.99%	1%	1%	1%	1.01%	1.01%	1%
Net Income+	-8.73M	-115.26M	-78.33M	-194.59M	-370.64M	-289.09M	-132.53M	-376.74M
Net Margin %	-	-	-4351.44%	-8108%	-7.15%	-4.75%	-0.35%	-5.93%
Net Income Growth %	-	-12.2%	0.32%	-1.48%	-0.9%	0.22%	0.54%	-1.84%
Net Income (Continuing)	-8.73M	-116.74M	-78.33M	-194.59M	-370.64M	-289.09M	-132.53M	-376.74M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.62	-3.28	-1.53	-5.49	-5.77	-4.13	-1.72	-4.58
EPS Growth %	-	-4.29%	0.53%	-2.59%	-0.05%	0.28%	0.58%	-1.66%
EPS (Basic)	-0.62	-3.28	-1.53	-5.49	-5.77	-4.13	-1.72	-4.58
Diluted Shares Outstanding	12.95M	35.14M	51.34M	46.73M	64.23M	70.02M	77.15M	82.31M
Basic Shares Outstanding	12.95M	35.14M	51.34M	46.73M	64.23M	70.02M	77.15M	82.31M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	2.04M	148.28M	94.54M	308.32M	1.27B	1.09B	1.21B	878.15M
Cash & Short-Term Investments	1.9M	146.44M	91.85M	299.67M	965.65M	1.08B	1.19B	850.74M
Cash Only	1.9M	146.44M	37.22M	162.17M	559.99M	232.77M	435.89M	281.97M
Short-Term Investments	0	0	54.63M	137.5M	405.65M	845.37M	753.98M	568.77M
Accounts Receivable	0	0	0	0	300M	0	0	0
Days Sales Outstanding	-	-	-	-	2.11K	-	-	-
Inventory	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	14.76M	21.17M	27.41M
Total Non-Current Assets+	365K	18.74M	61.55M	143.36M	201.45M	248.82M	248.67M	225.68M
Property, Plant & Equipment	335K	16.94M	43.25M	125.37M	186.98M	234.13M	237.81M	216.28M
Fixed Asset Turnover	-	-	0.00x	0.00x	0.28x	0.26x	1.59x	0.29x
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0
Long-Term Investments	30K	1.49M	0	0	0	0	0	0
Other Non-Current Assets	0	300K	18.31M	17.98M	14.47M	14.69M	10.87M	9.4M
Total Assets+	2.4M	167.01M	156.1M	451.68M	1.47B	1.34B	1.46B	1.1B
Asset Turnover	-	-	0.00x	0.00x	0.04x	0.05x	0.26x	0.06x
Asset Growth %	-	68.53%	-0.07%	1.89%	2.26%	-0.09%	0.09%	-0.24%
Total Current Liabilities+	6.57M	25.59M	29.14M	102.34M	213.44M	223.59M	205.56M	182.07M
Accounts Payable	726K	7.35M	7.85M	6.31M	7.47M	9.03M	1.62M	3.87M
Days Payables Outstanding	-	79.21	52.43	22.34	11.75	10.58	-	3.84
Short-Term Debt	1.01M	0	1.3M	2.12M	2.29M	0	0	0
Deferred Revenue (Current)	-1000K	0	0	24K	1000K	1000K	1000K	1000K
Other Current Liabilities	4.7M	16.54M	12.56M	83.02M	60.83M	49.68M	100.69M	19.74M
Current Ratio	0.31x	5.79x	3.24x	3.01x	5.96x	4.89x	5.89x	4.82x
Quick Ratio	0.31x	5.79x	3.24x	3.01x	5.96x	4.89x	5.89x	4.82x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	20K	7.4M	26.02M	103.78M	434.28M	384.64M	272.82M	188.21M
Long-Term Debt	0	0	4.41M	5.29M	3.01M	0	0	0
Capital Lease Obligations	0	0	21.19M	96.01M	134.81M	168.63M	159.91M	147.96M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	20K	7.4M	418K	2.08M	34.16M	13.84M	3.02M	7.04M
Total Liabilities	6.58M	32.98M	55.15M	206.12M	647.72M	608.24M	478.38M	370.28M
Total Debt+	1.01M	0	31.24M	107.64M	147.64M	179M	172.69M	161.43M
Net Debt	-891K	-146.44M	-5.98M	-54.53M	-412.35M	-53.76M	-263.21M	-120.54M
Debt / Equity	-	-	0.31x	0.44x	0.18x	0.24x	0.18x	0.22x
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-401.89x	-	-	-	-	-
Total Equity+	-4.18M	134.03M	100.94M	245.56M	826.74M	733.47M	981.33M	733.54M
Equity Growth %	-	33.04%	-0.25%	1.43%	2.37%	-0.11%	0.34%	-0.25%
Book Value per Share	-0.32	3.81	1.97	5.25	12.87	10.48	12.72	8.91
Total Shareholders' Equity	-4.18M	134.03M	100.94M	245.56M	826.74M	733.47M	981.33M	733.54M
Common Stock	5K	56K	73K	573K	684K	712K	816K	836K
Retained Earnings	-9.46M	-124.72M	-203.04M	-397.64M	-768.27M	-1.06B	-1.19B	-1.57B
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	-11K	-661K	16K	-9K	-50K	-2.43M	604K	679K
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-2.71M	-20.3M	-72M	-95.74M	-66.27M	22.53M	-149.19M	-347.25M
Operating CF Margin %	-	-	-4000.17%	-3989.21%	-1.28%	0.37%	-0.4%	-5.47%
Operating CF Growth %	-	-6.5%	-2.55%	-0.33%	0.31%	1.34%	-7.62%	-1.33%
Net Income	-8M	-116.74M	-78.33M	-194.59M	-370.64M	-289.09M	-132.53M	-376.74M
Depreciation & Amortization	11K	650K	3.5M	4.74M	7.45M	14.15M	20.01M	21.93M
Stock-Based Compensation	198K	7M	7.03M	15.38M	43.57M	84.32M	98.65M	120.66M
Deferred Taxes	500K	11.75M	0	63.52M	0	0	0	0
Other Non-Cash Items	3.85M	66.96M	6.5M	9.87M	142.09M	-38.48M	-18.87M	-2.87M
Working Capital Changes	740K	10.07M	-10.71M	5.35M	111.25M	251.63M	-116.45M	-110.22M
Change in Receivables	0	0	0	0	-300M	300M	0	0
Change in Inventory	0	0	0	0	0	-300M	0	0
Change in Payables	726K	2.44M	4.09M	60K	818K	2.37M	-7.58M	1.81M
Cash from Investing+	-346K	-13.42M	-66.66M	-100.12M	-294.14M	-461.34M	71.84M	185.01M
Capital Expenditures	-346K	-13.12M	-12.52M	-16.36M	-46.81M	-48.95M	-33.73M	-8.95M
CapEx % of Revenue	-	-	695.44%	681.54%	0.9%	0.8%	0.09%	0.14%
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	0	-300K	0	-83.77M	0	-412.38M	0	0
Cash from Financing+	4.98M	179.73M	41.28M	322.32M	756.14M	111.59M	276.45M	7.74M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	0	10K	-2.34M	1.1M	810K	5.62M	8.53M	0
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-3.05M	-33.42M	-84.52M	-112.1M	-113.08M	-26.42M	-182.93M	-356.19M
FCF Margin %	-	-	-4695.61%	-4670.75%	-2.18%	-0.43%	-0.48%	-5.61%
FCF Growth %	-	-9.95%	-1.53%	-0.33%	-0.01%	0.77%	-5.92%	-0.95%
FCF per Share	-0.24	-0.95	-1.65	-2.40	-1.76	-0.38	-2.37	-4.33
FCF Conversion (FCF/Net Income)	0.31x	0.18x	0.92x	0.49x	0.18x	-0.08x	1.13x	0.92x
Interest Paid	0	0	187K	0	567K	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-177.53%	-66.67%	-112.32%	-69.13%	-37.06%	-15.46%	-43.94%
Return on Invested Capital (ROIC)	-	-	-136.57%	-69.63%	-97.24%	-46.41%	-18.94%	-46.83%
Gross Margin	-	-	-303338.89%	-429812.5%	-347.75%	-411.48%	100%	-478.67%
Net Margin	-	-	-435144.44%	-810800%	-714.91%	-474.54%	-35.09%	-593.13%
Debt / Equity	-	-	0.31x	0.44x	0.18x	0.24x	0.18x	0.22x
Interest Coverage	-	-	-401.89x	-	-	-	-	-
FCF Conversion	0.31x	0.18x	0.92x	0.49x	0.18x	-0.08x	1.13x	0.92x
Revenue Growth	-	-	-	33.33%	215916.67%	17.51%	520.01%	-83.18%

Frequently Asked Questions

Growth & Financials

Beam Therapeutics Inc. (BEAM) reported $55.7M in revenue for fiscal year 2024.

Beam Therapeutics Inc. (BEAM) saw revenue decline by 83.2% over the past year.

Beam Therapeutics Inc. (BEAM) reported a net loss of $414.6M for fiscal year 2024.

Dividend & Returns

Beam Therapeutics Inc. (BEAM) has a return on equity (ROE) of -43.9%. Negative ROE indicates the company is unprofitable.

Beam Therapeutics Inc. (BEAM) had negative free cash flow of $352.4M in fiscal year 2024, likely due to heavy capital investments.